ReviewThe journal of pathology. Clinical research2025
Histopathology-based assessment of the tumour microenvironment in gastrointestinal cancers: practical approaches to prognostication and treatment stratification.
Review in The journal of pathology. Clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumour microenvironment (TME) is a key factor in carcinogenesis by affecting tumour growth, invasion, metastasis, and drug resistance. Histopathology and immunohistochemistry provide accessible and reproducible methodologies for TME evaluation, with growing evidence supporting their prognostic and predictive significance in gastrointestinal cancers. This commentary examines four papers published in the Journal of Pathology: Clinical Research that illustrate this methodology across various gastrointestinal cancers. The Tumour Microenvironment Score, Combined Immune Checkpoint Stromal Score, Immune Score for Gastric Cancer, and the multicomponent microenvironment and tumour inflammatory features panel have been developed to assess TME characteristics in colorectal cancer, gastric cancer, and gastroenteropancreatic neuroendocrine neoplasm. The reviewed studies demonstrate that basic morphological characteristics together with the expression of immune checkpoint markers and immune cell markers enable the development of effective clinical tools to enhance risk assessment and treatment planning. These practical, cost-effective, and promising methods need to undergo extensive multicentre testing with established protocols, digital pathology, and molecular information integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.